Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Media

AIM Rule 26

Regulatory news

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Welcome to N4 Pharma’s educational series, where we take a closer look at the science behind RNA therapeutics and how our Nuvec® gene delivery platform is advancing the field.

In this first video, we introduce N4 Pharma’s strategy—from developing Nuvec® as a next-generation RNA delivery system to building out our pipeline with novel gene therapies. Nuvec® offers unique advantages, including multi-RNA delivery, stability, ease of manufacturing, and protection of the RNA payload. Our lead programme, N4 101, is focused on inflammatory bowel disease (IBD), a market expected to reach $27.6bn by 2030.

Our goal? To drive shareholder value by securing licensing deals for Nuvec® while advancing N4 101 and future in-house therapies for urgent unmet medical needs.

Watch now to learn how we are positioning Nuvec® as a potential game-changer in RNA therapeutics—and stay tuned as we explore more in upcoming videos. If you have any questions, share them below and our experienced team will get back to you.

Inside N4 Pharma: Our Strategy for the Future